Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

December 27, 2013
Otsuka Pharmaceutical

European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
December 11, 2013
Otsuka Pharmaceutical

Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer's Disease
December 4, 2013
Otsuka Pharmaceutical

Providing Free Health Care to Over 700,000 Afghan Refugees : The 10th Anniversary of the "Otsuka Welfare Clinic"
November 25, 2013
Otsuka Pharmaceutical

CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
November 25, 2013
Otsuka Pharmaceutical

New From the US, A Smart New Way to Take Vitamin and Mineral Supplements VitaMelts® Dissolve Smoothly Without Water Available at Convenience Stores Throughout Japan From November 25
November 21, 2013
Otsuka Pharmaceutical

Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
November 21, 2013
Otsuka Holdings

OTSUKA AND LUNDBECK’S ONCE-MONTHLY ABILIFY MAINTENA® (ARIPIPRAZOLE) NOW APPROVED IN EUROPE FOR MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULT PATIENTS STABILIZED WITH ORAL ARIPIPRAZOLE
November 14, 2013
Otsuka Holdings

Otsuka Foods Announces Personnel Changes
November 13, 2013
Otsuka Holdings

Notice Regarding Change in Business Year
November 13, 2013
Otsuka Holdings

Otsuka Holdings Announces Personnel Changes
November 11, 2013
Taiho Pharmaceutical

Phase III Clinical Trial Results of TS-1 on Metastatic Colorectal Cancer Published in Digital Version of The Lancet Oncology
October 31, 2013
Otsuka Pharmaceutical

Otsuka Named as Lundbeck's Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption
October 25, 2013
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory launches a newly approved plasma substitute Voluven®6% on October 25, 2013
October 24, 2013
Otsuka Holdings

Otsuka announces 2013 third quarter U.S. net sales figures of ABILIFY®
October 23, 2013
Otsuka Pharmaceutical

Get the Dietary Fiber That is Missing From Your Diet*1With a Healthy Combination of Cereal Grains Otsuka Launches the New Products "Gerblé Multicereal Chocolate" and "Gerblé Multicereal Apricot"
October 11, 2013
Otsuka Holdings

Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals
October 10, 2013
Otsuka Pharmaceutical

Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease
October 7, 2013
Otsuka Holdings

Otsuka Holdings Announces Expiration of HSR Waiting Period for Astex Tender Offer
October 1, 2013
Otsuka Pharmaceutical

Otsuka Pharmaceutical Receives the 2013 Good Design Award for the Antiplatelet Drug "Pletaal® OD Tablets"
September 25, 2013
Taiho Pharmaceutical

Cancer Pain Reliever E-fen Buccal Tablets Launched
September 20, 2013
Otsuka Pharmaceutical

Otsuka And Lundbeck Receive Postive Chmp Opinion In Europe For Abilify Maintena™, A Once-Monthly Injectable For Schizophrenia
September 18, 2013
Otsuka Pharmaceutical

Two New Flavors of SoyCarat Nori & Natto and Olive Oil & Garlic Flavors Debut October 2
September 17, 2013
Otsuka Pharmaceutical

Vasopressin V2 Receptor Antagonist Samsca®7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
September 14, 2013
Otsuka Holdings

Otsuka Pharmaceutical Commences Tender Offer to Acquire All Outstanding Shares of Astex Pharmaceuticals
September 11, 2013
Taiho Pharmaceutical

Results of a Clinical Trial (JACCRO GC-05) of Second-line TS-1 Therapy on Patients with Unresectable or Recurrent Gastric Cancer That Is Refractory to Initial Therapy with TS-1
September 5, 2013
Otsuka Pharmaceutical

UL•OS Line of Men's Skin Care Marks 5th Anniversary Now Effective in Minimizing the Appearance of Fine Lines and Wrinkles Caused by Dryness
September 5, 2013
Otsuka Holdings

Otsuka Pharmaceutical to AcquireAstex Pharmaceuticals
August 30, 2013
Otsuka Pharmaceutical

Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease
August 28, 2013
Otsuka Pharmaceutical

Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launched on August 29
August 19, 2013
Otsuka Pharmaceutical

On September 1, Otsuka Launches "Omugi Seikatsu," a Healthy Breakfast Food With Barley Beta-Glucans